Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Govitecan-hziy/Sabizabulin Combination Therapy for the Treatment of Metastatic Triple Negative Breast Cancer
Latest Information Update: 10 Feb 2022
Price :
$35 *
At a glance
- Drugs Sabizabulin (Primary) ; Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms VERU-111
- Sponsors Veru Healthcare
- 24 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Oct 2021 Planned initiation date changed from 30 Sep 2021 to 30 Dec 2021.
- 25 Jun 2021 According to a Veru media release, company plans to commence this study in Q3 2021.